Abstract: The invention relates to a downmodulator of CUB domain-containing protein 1 (CDCP1), for use in a method of treating a patient suffering from castrate-resistant prostate cancer. The invention further relates to a pharmaceutical composition, comprising a downmodulator of CDCP1 and a senolytic compound, and to methods of selecting a patient with prostate cancer eligible for treatment with a combination of downmodulator of CDCP1 and a senolytic compound.

Abstract: Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non-psychedelic/psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).

Abstract: The use of Salvia haenkei extract as an active agent in the treatment of dermatological diseases is described. Also described are pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of dermatological diseases.

Abstract: The use of Salvia haenkei extract is described as a re-epithelizing and cicatrizing agent in the treatment of tissue lesions. Pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients for use in the treatment of tissue lesions are also disclosed.

Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.

Abstract: The present invention relates to the use of ALK tyrosine-kinase receptor inhibitors, in particular Alectinib, and compositions including it, as senolytic drug. In particular it relates to the use as senolytic drugs in a method of treatment of tumour or other pathological and incapacitating conditions associated to the cellular senescence.

Abstract: The use of Salvia haenkei extract is described as a re-epithelizing and cicatrizing agent in the treatment of tissue lesions. Pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients for use in the treatment of tissue lesions are also disclosed.

Abstract: The use of Salvia haenkei extract as an active agent in the treatment of dermatological diseases is described. Also described are pharmaceutical compositions comprising Salvia haenkei extract and suitable pharmaceutically acceptable excipients, for use in the treatment of dermatological diseases.

Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.

Abstract: The present invention refers to a novel in vitro method for detecting anti-senescence or pro-senescence activity of a compound, and to compounds with anti-senescence activity detected by said method, in particular to Salvia Haenkei extracts, and to compositions comprising said extracts.

Abstract: The present invention refers to a novel in vitro method for detecting anti-senescence or pro-senescence activity of a compound, and to compounds with anti-senescence activity detected by said method, in particular to Salvia Haenkei extracts, and to compositions comprising said extracts.